Advertisement

The Clinical Pharmacology of Cytosine Arabinoside

  • M. L. Slevin
  • E. M. Piall
  • G. W. Aherne
  • A. Johnston
  • T. A. Lister
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 28)

Abstract

There is now little doubt that a proportion of patients with adult acute myelogenous leukaemia will achieve long-term survival and possibly cure with combination chemotherapy. Cytosine arabinoside (araC) is one of the most important drugs used in the treatment of this disease. Despite extensive clinical experience over the past 15 years, the schedule of administration remains controversial. These studies were conducted in an attempt to provide a greater understanding of the effect of both the schedule and route of administration on the clinical pharmacology of araC.

Keywords

Acute Myelogenous Leukaemia Cytosine Arabinoside Subcutaneous Infusion Venous Infusion Neoplastic Meningitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bell R, Rohatiner AZS, Slevin ML, Ford JM, Dhaliwal HS, Henry G, Birkhead BG, Amess JAL, Malpas JS, Lister TA (1982) Short-term therapy for acute myelogenous leukaemia. Br Med J 284: 1221CrossRefGoogle Scholar
  2. 2.
    Canellos GD, Skarin AT, Ervin T, Weinstein H (1979) A chemotherapeutic approach to CNS lymphoma and leukaemia by the systemic administration of high dose of antimetabolites. In: Whitehouse JMA, Kay HEM (eds) CNS complications of malignant disease. pp 142–147Google Scholar
  3. 3.
    Early AP, Preisler HD, Slocum H, Rustum YM (to be published) A pilot study of high-dose cytosine arabinoside for acute leukaemia and refractory lymphoma. Clinical response and pharmacology. Cancer ResGoogle Scholar
  4. 4.
    Finklestein JZ, Scher J, Karon M (1970) Pharmacologic studies of tritiated cytosine arabinoside in children. Cancer Chemother Rep 54: 35–39PubMedGoogle Scholar
  5. 5.
    Grossman S, Thompson G, Trump D (1981) Cerebrospinal fluid (CSF) flow abnormalities in patients with neoplastic meningitis (NM). Proc Am Soc Clin Oncol 22: 382Google Scholar
  6. 6.
    Ho DHW, Frei E (1971) Clinical pharmacology of 1-B-D-Arabinofuranosylcytosine. Clin Pharmacol Ther 12: 944–954PubMedGoogle Scholar
  7. 7.
    Jeffreys DB, Pickup JC, Haw CM, Keen H (1979) Subcutaneous desferrioxamine infusion for haemachromatosis. Lancet II (8156/7): 1364–1365CrossRefGoogle Scholar
  8. 8.
    Karanes C, Wolfe SN, Herzig GP, Phillips GL, Lazarus HM, Herzig RH (1980) High-dose cytosine arabinoside (araC) in the treatment of patients with acute non-lymphocytic leukaemia (ANLL). Blood Abstr 504: 191 aGoogle Scholar
  9. 9.
    Piall EM, Aherne GW, Marks VM (1979) A radioimmunoassay for cytosine arabinoside. Br J Cancer 40: 548–556PubMedCrossRefGoogle Scholar
  10. 10.
    Pickup JC, Keen H (1980) Continuous subcutaneous insulin infusion: a developing tool in diabetes research. Diabetologia 18 (1): 1–4PubMedCrossRefGoogle Scholar
  11. 11.
    Rai KR, Glidewell O, Weinberg V, Holland JF (1981) Long-term remission in acute myelocytic leukaemia (AML): Report of a multi-institutional co-operative study. Proc Am Soc Clin 22: 481Google Scholar
  12. 12.
    Rees JKH, Sandler RM, Challener J, Hayhoe FCJ (1977) Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT. Br J Cancer 36: 770–776PubMedCrossRefGoogle Scholar
  13. 13.
    Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA (1981) The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. Br J Clin Pharmacol 12:507–510PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • M. L. Slevin
  • E. M. Piall
  • G. W. Aherne
  • A. Johnston
  • T. A. Lister

There are no affiliations available

Personalised recommendations